Investor Alert

Dow Jones Newswires Archives | Email alerts

Oct. 25, 2021, 1:31 a.m. EDT

Novartis Cancer Drug Trial Doesn't Meet Primary Endpoints

Watchlist Relevance

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

or Cancel Already have a watchlist? Log In

Novartis AG said Monday that a Phase 3 trial to evaluate a drug for use in lung cancer patients didn't meet its primary endpoints.

The Swiss pharma major said the trial, named CANOPY-1, didn't demonstrate statistical significance in overall survival and progression-free survival, meaning the time that a patient can live without the disease progressing.

The trial evaluated canakinumab, a monoclonal antibody, in combination with chemotherapy for patients with non-small cell lung cancer.

Write to Cecilia Butini at cecilia.butini@wsj.com

Get news alerts on Novartis AG ADR — or create your own.
This Story has 0 Comments
Be the first to comment
More News In
Dow Jones Newswires

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.